Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Expects to Net $90.5M from Offering

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sequenom said today that the underwriters of its public offering announced yesterday have exercised in full an option to purchase an additional 2.1 million shares of the firm's common stock at a price of $6 per share.

The San Diego-based molecular diagnostics developer said that it now expects gross proceeds of $96.6 million from the offering, or around $90.5 million in net proceeds. The funds will be used to support ongoing testing and development of its trisomy 21 non-invasive, pre-natal test, and possibly for acquisitions or investments in complementary businesses, Sequenom said in its prospectus for the offering.

The firm had announced yesterday the public offering of 14 million shares at $6 per share. With the overallotment option, the total number of shares offered was 16.1 million.

In early Friday trade on the Nasdaq, shares of Sequenom were down 2 percent at $6.62.

The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.